

Applicants: Norman Latov and Armin Alaedini  
U.S. Serial No.: 09/825,572  
Filed: April 3, 2001  
Page 2

Please amend the subject application as follows:

In the Claims

Please cancel claims 13, 23, 24, and 25 without prejudice or disclaimer to applicants' right to pursue the subject matter of these claims in a continuation or other application.

Please amend claims 1, 4, 9, 20, and 26 as follows:

- A1
1. (Amended) A method of detecting antibodies in a blood or blood derivative solution comprising:
    - a) contacting the blood or blood derivative solution with a ganglioside-coated surface of a sensor chip under conditions that permit the antibodies to bind to the ganglioside coating;
    - b) detecting a change in surface plasmon resonance signal of the sensor chip resulting from the antibodies binding to the ganglioside coating.

- A2
2. (Amended) The method of claim 1, wherein the antibody is an anti-ganglioside antibody.

- A3
3. (Amended) The method of claim 1, wherein the control antigen is Ganglioside GM2.

- A4
- 10  
20. (Amended) The method of claim 1, wherein the surface plasmon resonance signal is increased by washing the solution from the surface of the sensor chip and applying a second solution containing a secondary antibody to the
- A

Applicants: Norman Latov and Armin Alaedini  
U.S. Serial No.: 09/825,572  
Filed: April 3, 2001  
Page 3

A4 con's surface.

A5 ¶ 26. (Amended) The method of claim 27, wherein the disease is Guillian-Barré syndrome, motor neuropathy, peripheral neuropathy, or an autoimmune neuropathy.

Please add new claim 27 as follows:

A6 ¶ 27. (New) A method of determining whether a subject is suffering from a neurological disease comprising:  
a) contacting the solution with a sensor chip comprising a ganglioside coated surface under conditions that permit anti-ganglioside antibodies to bind to the ganglioside coating and the sensor chip to emit a surface plasmon resonance signal; and  
b) detecting a change in the surface plasmon resonance signal emitted by the sensor chip so as to thereby detect the binding of the antibodies to the ganglioside coating,  
wherein detection of the change in surface plasmon resonance signal indicates the subject is suffering from the neurological disease.

A mark-up copy of the claims is annexed hereto as **Exhibit A**.

REMARKS

Claims 1-26 are pending in the subject application, with claims 2, 3, 5, 8, 15-19, 21, and 22 withdrawn from consideration. Applicants

7